[Federal Register Volume 84, Number 229 (Wednesday, November 27, 2019)]
[Notices]
[Pages 65424-65426]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25788]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-608; NRC-2019-0173]


SHINE Medical Technologies, LLC

AGENCY: Nuclear Regulatory Commission.

ACTION: Intent to prepare a supplement to the final environmental 
impact statement and conduct scoping.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) intends to gather 
information through the public scoping process to prepare a supplement 
the to the final environmental impact statement (FEIS) on the 
construction permit related to the operating license application for 
the SHINE Medical Isotope Production Facility. The NRC is seeking 
public input on the proposed action and has scheduled a public scoping 
meeting.

DATES: Submit comments by January 13, 2020. Comments received after 
this date will be considered if it is practical to do so, but the 
Commission is able to ensure consideration only for comments received 
before this date.

ADDRESSES: You may submit comments by any of the following methods:
     Federal Rulemaking Website: Go to http://www.regulations.gov and search for Docket ID NRC-2019-0173. Address 
questions about NRC docket IDs in Regulations.gov to Jennifer Borges; 
telephone: 301-287-9127; email: [email protected]. For technical 
questions, contact the individual listed in the FOR FURTHER INFORMATION 
CONTACT section of this document.
     Mail comments to: Office of Administration, Mail Stop: 
TWFN-7-A60M, U.S. Nuclear Regulatory Commission, Washington, DC 20555-
0001, ATTN: Program Management, Announcements and Editing Staff.
     For additional direction on obtaining information and 
submitting comments, see ``Obtaining Information and Submitting 
Comments'' in the SUPPLEMENTARY INFORMATION section of this document.

FOR FURTHER INFORMATION CONTACT: Jennifer A. Davis, Office of Nuclear 
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission,

[[Page 65425]]

Washington, DC 20555-0001, telephone: 301-415-3835; email: 
[email protected].

SUPPLEMENTARY INFORMATION:

I. Obtaining Information and Submitting Comments

A. Obtaining Information

    Please refer to Docket ID NRC-2019-0173 when contacting the NRC 
about the availability of information regarding this document. You may 
obtain publicly-available information related to this document by any 
of the following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC-2019-0173.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the NRC 
Library at https://www.nrc.gov/reading-rm/adams.html. To begin the 
search, select ``Begin Web-based ADAMS Search.'' For problems with 
ADAMS, please contact the NRC's Public Document Room (PDR) reference 
staff at 1-800-397-4209, 301-415-4737, or by email to 
[email protected]. The ADAMS accession number for each document 
referenced in this document (if that document is available in ADAMS) is 
provided the first time that a document is referenced. SHINE Medical 
Technologies, LLC's (SHINE) operating license application for the SHINE 
Medical Isotope Production Facility can be found in ADAMS under Package 
Accession No. ML19211C143.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.
     Library: A copy of the SHINE supplemental environmental 
report (ER) is available at the Hedberg Public Library, 316 South Main 
Street, Janesville, Wisconsin 53545.

B. Submitting Comments

    Please include Docket ID NRC-2019-0173 in the subject line of your 
comment submission in order to ensure that the NRC is able to make your 
comment submission available to the public in this docket.
    The NRC cautions you not to include identifying or contact 
information that you do not want to be publicly disclosed in your 
comment submission. The NRC will post all comment submissions at 
https://www.regulations.gov as well as enter the comment submissions 
into ADAMS. The NRC does not routinely edit comment submissions to 
remove identifying or contact information.
    If you are requesting or aggregating comments from other persons 
for submission to the NRC, then you should inform those persons not to 
include identifying or contact information that they do not want to be 
publicly disclosed in their comment submission. Your request should 
state that the NRC does not routinely edit comment submissions to 
remove such information before making the comment submissions available 
to the public or entering the comment submissions into ADAMS.

II. Discussion

    By letter dated July 17, 2019 (ADAMS Accession No. ML19211C044), 
SHINE filed with the NRC, pursuant to Section 103 of the Atomic Energy 
Act and part 50, ``Domestic Licensing of Production and Utilization 
Facilities,'' of title 10 of the Code of Federal Regulations (10 CFR), 
an application for a 30-year operating license for the SHINE Medical 
Isotope Production Facility to be located in Janesville, Wisconsin 
(ADAMS Package Accession No. ML19211C143). In addition to general and 
financial information, the application included a final safety analysis 
report and a supplemental ER. A notice of receipt and availability of 
this application was previously published in the Federal Register (FR) 
on September 10, 2019 (84 FR 47557). A notice of acceptance of the 
application for docketing was published in the FR on October 15, 2019 
(84 FR 55187). In accordance with the provisions of 10 CFR 2.105, 
``Notice of proposed action,'' a separate notice of opportunity to file 
a petition for leave to intervene in a hearing will be published at a 
later date.
    SHINE has proposed to construct and operate a facility in 
Janesville, Wisconsin to produce molybdenum-99 through the irradiation 
and processing of a uranyl sulfate solution. As described in the 
operating license application, the proposed SHINE facility would 
comprise an irradiation facility and radioisotope production facility. 
The irradiation facility would consist of eight subcritical operating 
assemblies (or irradiation units) and the radioisotope production 
facility would consist of hot cell structures for the processing of 
irradiated material.
    By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. 
ML13088A192 and ML13172A361, respectively), SHINE (at the time known as 
SHINE Medical Technologies, Inc.) submitted a construction permit 
application, as updated in 2015, for its eight utilization facilities 
and one production facility (ADAMS Package Accession No. ML15258A431). 
The NRC issued Construction Permit No. CPMIF-001 to SHINE on February 
29, 2016 (ADAMS Package Accession No. ML16041A473), as supported by 
NUREG-2189, ``Safety Evaluation Report Related to SHINE Medical 
Technologies, Inc. Construction Permit Application for a Medical 
Radioisotope Production Facility,'' dated August 2016 (ADAMS Accession 
No. ML16229A140), and NUREG-2183, ``Environmental Impact Statement for 
the Construction Permit for the SHINE Medical Radioisotope Production 
Facility,'' dated October 2015 (ADAMS Accession No. ML15288A046). In 
accordance with 10 CFR 51.95(b), in connection with SHINE's operating 
license application, the NRC will prepare a supplement to NUREG-2183, 
which will update the prior environmental review. The supplement will 
only cover matters that differ from or reflect significant new 
information concerning matters discussed in NUREG-2183.

III. Request for Comments

    This notice informs the public of the NRC's intention to conduct 
scoping and prepare a supplement to NUREG-2183 as part of the review of 
the SHINE operating license application, and to provide the public an 
opportunity to participate in the environmental scoping process, as 
defined in 10 CFR 51.29, ``Scoping-environmental impact statement and 
supplement to environmental impact statement.''
    The regulations in 36 CFR 800.8, ``Coordination with the National 
Environmental Policy Act,'' allow agencies to use their National 
Environmental Policy Act of 1969 (NEPA) process to fulfill the 
requirements of Section 106 of the National Historic Preservation Act 
(NHPA). Therefore, pursuant to 36 CFR 800.8(c), the NRC intends to use 
its NEPA process and documentation to comply with Section 106 of the 
NHPA in lieu of the procedures set forth at 36 CFR 800.3 through 800.6.
    In accordance with 10 CFR 51.53(b), SHINE submitted a supplement to 
its construction permit ER as part of the operating license 
application. The supplement updates the information presented in the 
previous ER submitted as part of the construction permit application. 
The supplemental ER was prepared pursuant to 10 CFR part 51 and is 
publicly available in ADAMS under Accession No. ML19211C139. The 
supplemental ER may also be viewed on the internet at https://www.nrc.gov/docs/ML1921/ML19211C139.pdf. In addition, a paper

[[Page 65426]]

copy of ER is available for public review at the Hedberg Public 
Library, 316 South Main Street, Janesville, Wisconsin 53545.
    When a FEIS has been prepared in connection with the issuance of a 
construction permit for a production or utilization facility, the NRC 
is required to prepare a supplement to the FEIS on the construction 
permit in connection with the issuance of an operating license in 
accordance with 10 CFR 51.95(b). The supplement will only cover matters 
that differ from the final environmental impact statement or that 
reflect significant new information concerning matters discussed in the 
final environmental impact statement.
    The NRC will first conduct scoping and will then prepare a draft 
supplement for public comment. Participation in the scoping process by 
members of the public and local, State, Tribal, and Federal government 
agencies is encouraged. The scoping process will be used to accomplish 
the following:
    a. Define the proposed action;
    b. Determine the scope and identify the significant issues to be 
analyzed in depth;
    c. Identify and eliminate from detailed study those issues that are 
peripheral or are not significant; or were covered by a prior 
environmental review;
    d. Identify any environmental assessments and other ElSs that are 
being or will be prepared that are related to, but are not part of, the 
scope of the supplement being considered;
    e. Identify other environmental review and consultation 
requirements related to the proposed action;
    f. Indicate the relationship between the timing of the preparation 
of the environmental analyses and the Commission's tentative planning 
and decision-making schedule;
    g. Identify any cooperating agencies and, as appropriate, allocate 
assignments for preparation and schedules for completing the 
supplement; and
    h. Describe how the supplement will be prepared, including any 
contractor assistance to be used.
    The NRC invites the following entities to participate in scoping:
    a. The applicant, SHINE;
    b. Any Federal agency that has jurisdiction by law or special 
expertise with respect to any environmental impact involved or that is 
authorized to develop and enforce relevant environmental standards;
    c. Affected State and local government agencies, including those 
authorized to develop and enforce relevant environmental standards;
    d. Any affected Indian Tribe;
    e. Any person who requests or has requested an opportunity to 
participate in the scoping process; and
    f. Any person who has petitioned or intends to petition for leave 
to intervene under 10 CFR 2.309.

IV. Public Scoping Meeting

    In accordance with 10 CFR 51.26, the scoping process may include a 
public scoping meeting to help identify significant issues related to a 
proposed activity and to determine the scope of issues to be addressed. 
The NRC will hold a public scoping meeting for the SHINE environmental 
review on December 12, 2019, from 6:00 p.m. to 8:00 p.m. at The Celtic 
House at Glen Erin Golf Club, 1417 W Airport Rd., Janesville, WI 53546. 
There will be an open house one hour before the meeting for members of 
the public to meet with the NRC staff and sign in to speak at the 
meeting.
    The meeting will be transcribed and will include: (1) An overview 
by the NRC staff of the safety and NEPA environmental review processes, 
the proposed scope of the supplement to the FEIS; and (2) the 
opportunity for interested government agencies, organizations, and 
individuals to submit comments or suggestions on the environmental 
issues or the proposed scope. The main objectives of this meeting are 
to describe the environmental review process and receive public 
comments on the appropriate scope and content to be considered in the 
staff's review. To be considered, comments must be provided either at 
the transcribed public meeting or in writing, as discussed in the 
ADDRESSES section of this document.
    Persons may register to attend or present oral comments at the 
meeting on the scope of the NEPA review by contacting the NRC 
Environmental Project Manager, Ms. Jennifer Davis, by telephone at 301-
415-3835, or by email at [email protected] no later than December 
5, 2019. Members of the public may also register to speak during the 
registration period prior to the start of the meeting. Individual oral 
comments may be limited by the time available, depending on the number 
of persons who register. Members of the public who have not registered 
may also have an opportunity to speak if time permits. Public comments 
will be considered in the scoping process for the SHINE environmental 
review. Please contact Ms. Davis no later than December 5, 2019, if 
accommodations or special equipment is needed to attend or present 
information at the public meeting, so that the NRC staff can determine 
whether the request can be accommodated.
    Participation in the scoping process does not entitle participants 
to become parties to the proceeding to which the supplement relates. 
Matters related to participation in any hearing are outside the scope 
of matters to be discussed at this public meeting.

    Dated at Rockville, Maryland, this 22nd day of November 2019.

    For the Nuclear Regulatory Commission.
Robert B. Elliott,
Chief, Environmental Review License Renewal Branch, Division of 
Rulemaking, Environmental, and Financial Support, Office of Nuclear 
Material Safety and Safeguards.
[FR Doc. 2019-25788 Filed 11-26-19; 8:45 am]
BILLING CODE 7590-01-P